Vasomedical
This article was originally published in The Gray Sheet
Executive Summary
Firm orchestrates a $3.5 mil. round of financing through the issuance of 5% Series C convertible preferred stock. Proceeds are tabbed to support expanded marketing initiatives aimed at increasing awareness among physicians, patients and insurers of the firm's EECP (enhanced external counterpulsation) non-invasive technology for treatment of angina pectoris in patients with coronary disease. Specific programs will include patient outreach initiatives and those aimed at demonstrating to HMOs the economic benefits of the device
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.